Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2025
SMC - August 2025 decisions
11 August 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 11 Aug 2025
PHARMAC to update access and supply of COVID-19 treatments
11 August 2025 - Pharmac will simplify the criteria for people accessing COVID-19 anti-viral medicines and will align the funding ...
Posted by Michael Wonder on 11 Aug 2025
Trump’s trade war is not the only threat to cheap PBS medicines
10 August 2025 - Australia’s health system is rightly celebrated for its universal access and cost effectiveness, but its outdated assessment ...
Posted by Michael Wonder on 10 Aug 2025
America’s drug regulator is in turmoil
10 August 2025 - The already fraught oversight of rare disease treatments is becoming politicised. ...
Posted by Michael Wonder on 09 Aug 2025
Labor ‘very concerned’ by Trump pharma threat
7 August 2025 - The Albanese Government says it is “very concerned” after Donald Trump’s latest tariff threat on a key ...
Posted by Michael Wonder on 09 Aug 2025
Imfinzi approved in Canada as first and only peri-operative immunotherapy for muscle invasive bladder cancer
6 August 2025 - Health Canada has granted a Notice of Compliance for Imfinzi (durvalumab) for the treatment of patients ...
Posted by Michael Wonder on 09 Aug 2025
International study on authorisation times confirms Swissmedic's competitiveness
6 August 2025 - Latest CIRS study rates Swissmedic's authorisation procedures for human medicinal products with new active substances as internationally ...
Posted by Michael Wonder on 09 Aug 2025
Medicines for chronic illnesses soon accessible before European authorisation
7 August 2025 - The scheme will be launched on 1 January 2026 and is expected to provide access to ...
Posted by Michael Wonder on 09 Aug 2025
Health Canada has authorised CSL's Andembry (garadacimab) as once monthly treatment for hereditary angioedema
8 August 2025 - CSL today announced that Health Canada has granted a marketing authorisation for Andembry (garadacimab) for routine ...
Posted by Michael Wonder on 09 Aug 2025
Labor vows to ‘fight’ as Trump threatens pharma tariffs
8 August 2025 - The Albanese government is vowing to “fight for the PBS” as Donald Trump tries to strong-arm ...
Posted by Michael Wonder on 09 Aug 2025
Arvinas announces FDA acceptance of the new drug application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced breast cancer
8 August 2025 - Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in ...
Posted by Michael Wonder on 08 Aug 2025
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
8 August 2025 - Today, the FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals), a kinase inhibitor, for ...
Posted by Michael Wonder on 08 Aug 2025
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder and adults with generalised myasthenia gravis
7 August 2025 - The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have ...
Posted by Michael Wonder on 08 Aug 2025
Access to multiple sclerosis treatments inadequate in British Columbia
7 August 2025 - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis, is calling for the provincial ...
Posted by Michael Wonder on 08 Aug 2025
PBS wait times a more urgent issue than Donald Trump's potential pharmaceutical tariffs, peak medicines body warns
7 August 2025 - Excessive wait times for medicines to be listed on the PBS are a much greater threat ...